Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer’s Disease 2019
01 Novembro 2019 - 9:00AM
Business Wire
- Presentation will detail impact of
Cortexyme’s lead compound, COR388, on ApoE in Alzheimer’s Disease
patients
- CTAD attendees are also invited to
educational session focused on Cortexyme’s new investigational
approach to AD treatment
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage
biopharmaceutical company pioneering a novel, disease-modifying
therapeutic approach to treat what it believes to be a key
underlying cause of Alzheimer’s and other degenerative diseases,
today announced that its lead investigational medicine, COR388,
will be the subject of an oral presentation at Clinical Trials on
Alzheimer’s Disease (CTAD) 2019. The company will also host a lunch
briefing on the preclinical and clinical data supporting COR388’s
mechanism of action, as well as its evaluation in the ongoing Phase
2/3 GAIN trial. CTAD brings together leaders in Alzheimer’s Disease
(AD) research and treatment to discuss new results, potential new
therapeutics and methodological issues involved in the development
of AD therapies, and will take place from December 4-7, 2019 in San
Diego.
“As an industry, we are seeing the conversation around
Alzheimer’s research move towards new, innovative approaches to
treatment which act upstream of Alzheimer’s pathology,” said Casey
Lynch, Cortexyme’s chief executive officer, chair, and co-founder.
“We’re looking forward to advancing that conversation at this
year’s CTAD conference. With both our oral presentation on Saturday
and our lunch briefing on Thursday, we hope to provide the
community with additional evidence behind the gingipain hypothesis,
including the downstream effects on genetic risk factors, abeta,
inflammation and neurodegeneration.”
Michael Detke, M.D., Ph.D., Cortexyme’s chief medical officer,
will lead the oral presentation. The presentation, abstract OC28,
is entitled, “COR388, A Novel Gingipain Inhibitor, Decreases
Fragmentation of ApoE in Alzheimer’s Disease Central Nervous
System,” and will take place on Saturday, December 7, at 10:00 a.m.
local time.
The lunch briefing, “P. gingivalis in Alzheimer's Disease
Brains: Evidence for Disease Causation and Treatment with COR388,”
will be open to all CTAD attendees, and will take place on
Thursday, December 5, from 12:30-1:30 p.m. in Room Sapphire E/F.
Attendees will have an opportunity to learn more about how
Cortexyme is targeting a potential root cause of AD, including
background on the ongoing Phase 2/3 GAIN Trial and the data
supporting the gingipain hypothesis, as well as Phase 1 a/b
biomarker and cognitive data. The GAIN Trial, investigating
Cortexyme’s lead compound COR388, is based on a growing body of
evidence supporting a key role for Porphyromonas gingivalis, the
bacterium most commonly associated with chronic periodontal
disease, and its proteolytic gingipains in the development of
AD.
For more information about CTAD 2019, including a full schedule
of presentations, visit the conference website. To secure your
reservation for Cortexyme’s lunch briefing, please register on the
event page.
About the GAIN Trial
The GAIN Trial is a Phase 2/3 randomized, double-blind,
placebo-controlled study assessing the efficacy, safety, and
tolerability of two dose levels of COR388 oral capsules in subjects
with mild to moderate AD. The trial is currently enrolling subjects
in the U.S. and Europe, and top-line results from the trial are
anticipated in the fourth quarter of 2021. More information about
the trial can be found at www.GAINtrial.com.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical
company pioneering a novel, disease-modifying therapeutic approach
to treat what it believes to be a key underlying cause of
Alzheimer’s disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead
investigational medicine, COR388, is the subject of the GAIN Trial,
an ongoing Phase 2/3 clinical study in patients with mild to
moderate Alzheimer’s. To learn more about Cortexyme, visit
www.cortexyme.com or follow @Cortexyme on Twitter.
Forward-Looking Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words.
Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. Factors that could cause
actual results to differ include, but are not limited to, the risks
and uncertainties described in the section titled “Risk Factors” in
the final prospectus related to Cortexyme’s initial public offering
filed with the Securities and Exchange Commission on May 9, 2019
and Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on June 12, 2019. Forward-looking statements
contained in this press release are made as of this date, and
Cortexyme undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191101005285/en/
Hal Mackins For Cortexyme hal@torchcomllc.com (415) 994-0040
Quince Therapeutics (NASDAQ:QNCX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Quince Therapeutics (NASDAQ:QNCX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024